Fred Alger Management, LLC Autolus Therapeutics PLC Transaction History

Fred Alger Management, LLC

  • $19.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$3.33 - $5.68 $3.95 Million - $6.74 Million
-1,186,614 Reduced 99.14%
10,262 $35,000
Q1 2024

May 15, 2024
SELL
$5.39 - $7.29 $848,682 - $1.15 Million
-157,455 Reduced 11.63%
1,196,876 $7.64 Million
Q4 2023

Feb 14, 2024
BUY
$2.13 - $6.63 $2.88 Million - $8.98 Million
1,354,331 New
1,354,331 $8.72 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email